AIA (01299) Announces Q3 Results: New Business Value Falls 5% to US$1.415 Billion
AIA (01299) has announced its Q3 2026 results. On a constant exchange rate basis, in Q3 2026, AIA's group new business value fell 5% to US$1.415 billion, reflecting declines in the Hong Kong business and the Chinese mainland business, partly offset by 18% new business value growth from the group's other reporting segments.
AIA (01299) Announces Q3 2026 Results: Group New Business Value Falls 5% to US$1.415 Billion
AIA (01299) has announced its results for the third quarter of 2026. On a constant exchange rate basis, in Q3 2026, AIA's group new business value fell 5% to US$1.415 billion, reflecting declines in the Hong Kong business and the Mainland China business, partly offset by 18% new business value growth from the Group's other reporting segments.
The Group's new business value rebounded strongly in September, growing more than 25% year-on-year. Overall, benefiting from a favourable shift in the Mainland China product and channel mix, the new business value margin rose 5.3 percentage points to 63.5%. Annualised new premiums decreased 13% to US$2.237 billion, mainly affected by the Mainland China business; total weighted premium income increased 7% to US$12.892 billion. The margin reported on a new business premium present value basis remained unchanged at 11%. As announced in the Group's 2026 interim results, the Group expects to exceed its target of 9% to 11% compound annual growth in operating profit after tax per share from 2023 to 2026.
New business value for the first nine months of 2026 rose 5% to US$4.627 billion, driven by growth across all reporting segments except the Thailand business.
Lee Yuan Siong, AIA Group Chief Executive and President, said: "AIA achieved 5% growth in new business value in the first nine months of 2026, although exceptionally high sales in the Hong Kong business and the Mainland China business in the same period last year affected third-quarter growth. The Group's new business value rebounded strongly in September, growing more than 25% year-on-year."
"The Group continues to see attractive growth opportunities across its markets. Customer demand for protection, health, savings and retirement solutions remains strong, and the Group is continuing to invest in its competitive advantages to capture these opportunities. The agency business foundation continues to strengthen, with the number of active agents, new recruits and new agency leaders all rising compared with last year; at the same time, the Group's cooperation with bank partners has further deepened."
"The Group enters the fourth quarter with strong momentum and remains confident in its outlook. As announced in the Group's 2026 interim results, the Group expects to exceed its target of 9% to 11% compound annual growth in operating profit after tax per share from 2023 to 2026, fully reflecting how the Group's profitable new business growth translates into higher earnings and creates long-term value for shareholders."
Related Articles

Chipmore Semiconductor (07672) opens its IPO subscription from October 30 to November 5, planning a global offering of 107 million H shares and introducing cornerstone investors including GF Fund and Guohui Hong Kong.

Hemei Pharmaceutical-B (00054) is conducting a public offering from October 30 to November 4, planning to globally offer 55.21 million H shares and introducing cornerstone investors including GF Fund Management and China Universal Asset Management.

HK Stock Concept Tracker | Overseas BD Transaction Value for Domestic Innovative Drugs Expected to Exceed US$150 Billion in 2026; Overseas Commercialization Entering a Phase of Intensive Realization (with Concept Stocks)
Chipmore Semiconductor (07672) opens its IPO subscription from October 30 to November 5, planning a global offering of 107 million H shares and introducing cornerstone investors including GF Fund and Guohui Hong Kong.

Hemei Pharmaceutical-B (00054) is conducting a public offering from October 30 to November 4, planning to globally offer 55.21 million H shares and introducing cornerstone investors including GF Fund Management and China Universal Asset Management.

HK Stock Concept Tracker | Overseas BD Transaction Value for Domestic Innovative Drugs Expected to Exceed US$150 Billion in 2026; Overseas Commercialization Entering a Phase of Intensive Realization (with Concept Stocks)






